Health

MrMed Expands Its Reach with New Bengaluru Cold-Chain Hub to Improve Access to GLP-1 and Critical Care Medicines

MrMed, India’s largest online super-specialty pharmacy, has opened a state-of-the-art cold-chain distribution hub in Bengaluru. The new facility strengthens the…

4 days ago

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN” or the…

5 days ago

Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the PARADIGM Trial)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company)…

5 days ago

Real-World Data Presented at TCT 2025 Demonstrates the EggNest Complete Radiation Protection System Significantly Reduces Radiation Exposure for the Entire Cath Lab Team

SAN FRANCISCO, Oct. 26, 2025 /PRNewswire/ -- At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The…

6 days ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced…

6 days ago

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…

6 days ago

Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…

7 days ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…

7 days ago

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings…

1 week ago

Shimadzu Asia Pacific Celebrates 150th Anniversary -A Century and a Half of Driving Healthcare and Technological Breakthroughs

SINGAPORE, Oct. 21, 2025 /PRNewswire/ -- Shimadzu Asia Pacific joins the global celebration of Shimadzu Corporation's 150th anniversary, marking a…

1 week ago